[In vitro activity of human recombinant interferon gamma against SARS-CoV-2 virus].

Q3 Medicine Voprosy virusologii Pub Date : 2023-03-11 DOI:10.36233/0507-4088-150

Y V Nikolaeva, A V Galochkina, A A Shtro, S A Berns

{"title":"[In vitro activity of human recombinant interferon gamma against SARS-CoV-2 virus].","authors":"Y V Nikolaeva, A V Galochkina, A A Shtro, S A Berns","doi":"10.36233/0507-4088-150","DOIUrl":null,"url":null,"abstract":"Introduction: The development of drugs against SARS-CoV-2 continues to be crucial for reducing the spread of infection and associated mortality. The aim of the work is to study the neutralization of the SARS-CoV-2 virus with interferon gamma preparations in vitro.Materials and methods: The activity of recombinant human interferon gamma for intramuscular and subcutaneous administration of 500,000 IU and for intranasal administration of 100,000 IU against the SARS-CoV-2 virus in vitro was studied. The methodological approach of this study is based on the phenomenon of a decrease in the number of plaques formed under the action of a potential antiviral drug.Results: The antiviral activity of recombinant interferon gamma has been experimentally confirmed, both in preventive and therapeutic application schemes. The smallest number of plaques was observed with the preventive scheme of application of the tested object at concentrations of 1000 and 333 IU/ml. The semi-maximal effective concentration (EC50) with the prophylactic regimen was 24 IU/ml.Discussion: The preventive scheme of application of the tested object turned out to be more effective than therapeutic one, which is probably explained by the launch of the expression of various interferon-stimulated genes that affect to a greater extent the steps of virus entry into the cell and its reproduction.Conclusion: Further study of the effect of drugs based on recombinant interferon gamma on the reproduction of the SARS-CoV-2 virus for clinical use for prevention and treatment is highly relevant.","PeriodicalId":23669,"journal":{"name":"Voprosy virusologii","volume":"68 1","pages":"26-36"},"PeriodicalIF":0.0000,"publicationDate":"2023-03-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Voprosy virusologii","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.36233/0507-4088-150","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The development of drugs against SARS-CoV-2 continues to be crucial for reducing the spread of infection and associated mortality. The aim of the work is to study the neutralization of the SARS-CoV-2 virus with interferon gamma preparations in vitro.

Materials and methods: The activity of recombinant human interferon gamma for intramuscular and subcutaneous administration of 500,000 IU and for intranasal administration of 100,000 IU against the SARS-CoV-2 virus in vitro was studied. The methodological approach of this study is based on the phenomenon of a decrease in the number of plaques formed under the action of a potential antiviral drug.

Results: The antiviral activity of recombinant interferon gamma has been experimentally confirmed, both in preventive and therapeutic application schemes. The smallest number of plaques was observed with the preventive scheme of application of the tested object at concentrations of 1000 and 333 IU/ml. The semi-maximal effective concentration (EC50) with the prophylactic regimen was 24 IU/ml.

Discussion: The preventive scheme of application of the tested object turned out to be more effective than therapeutic one, which is probably explained by the launch of the expression of various interferon-stimulated genes that affect to a greater extent the steps of virus entry into the cell and its reproduction.

Conclusion: Further study of the effect of drugs based on recombinant interferon gamma on the reproduction of the SARS-CoV-2 virus for clinical use for prevention and treatment is highly relevant.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

[人重组干扰素γ体外抗SARS-CoV-2病毒活性]。

针对SARS-CoV-2的药物开发对于减少感染传播和相关死亡率仍然至关重要。本研究的目的是研究干扰素γ制剂对SARS-CoV-2病毒的体外中和作用。材料与方法:研究重组人γ干扰素在肌肉和皮下分别给药50万IU和鼻腔分别给药10万IU的条件下对SARS-CoV-2病毒的体外活性。本研究的方法学方法是基于一种潜在的抗病毒药物作用下形成的斑块数量减少的现象。结果:重组干扰素γ的抗病毒活性已被实验证实，在预防和治疗应用方案。使用浓度为1000和333 IU/ml的被试物的预防方案观察到斑块数量最少。预防方案半最大有效浓度(EC50)为24 IU/ml。讨论:应用被试对象的预防方案比治疗方案更有效，这可能是由于干扰素刺激的各种基因的表达在更大程度上影响病毒进入细胞及其繁殖的步骤。结论:进一步研究以重组干扰素γ为基础的药物对SARS-CoV-2病毒繁殖的影响，对临床应用于防治具有重要意义。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Voprosy virusologii Medicine-Infectious Diseases

CiteScore

2.00

自引率

0.00%

发文量

期刊介绍： The journal deals with advances in virology in Russia and abroad. It publishes papers dealing with investigations of viral diseases of man, animals and plants, the results of experimental research on different problems of general and special virology. The journal publishes materials are which promote introduction into practice of the achievements of the virological science in the eradication and incidence reduction of infectious diseases, as well as their diagnosis, treatment and prevention. The reader will find a description of new methods of investigation, new apparatus and devices.